Regeneron Wins Bid for 23andMe Assets for $256 Million
Deal News | May 19, 2025 | Wachtell, Lipton, Rosen & Katz
Regeneron Pharmaceuticals, Inc. has successfully acquired substantially all assets of 23andMe for $256 million. The deal was concluded on May 19, 2025, after Regeneron won the auction held under Section 363 of the U.S. Bankruptcy Code. Prestigious law firm Wachtell, Lipton, Rosen & Katz served as the legal advisor for Regeneron in this acquisition. This transaction allows Regeneron to further enrich its genomic insights platform, potentially enhancing its research and developmental capabilities.
Sectors
- Biotechnology
- Legal Services
Geography
- United States – The acquisition took place under the U.S. Bankruptcy Code, involving American companies Regeneron and 23andMe.
Industry
- Biotechnology – The article focuses on Regeneron Pharmaceuticals, a biotechnology company, acquiring assets related to genetic insights.
- Legal Services – Wachtell, Lipton, Rosen & Katz, a prominent law firm, provided legal advisory services for the acquisition.
Financials
- $256 million – The acquisition price paid by Regeneron for substantially all of 23andMe's assets.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | Bidding Company | Company | A biotechnology company engaged in research and development. |
| 23andMe | Target Company | Company | A personal genomics and biotechnology company. |
| Wachtell, Lipton, Rosen & Katz | Legal Advisor | Company | A prestigious law firm providing legal guidance to Regeneron for the acquisition. |